Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma

Marek Trněný • 12 Jun 2015
EHA 2015
Mantle Cell Lymphoma Lenalidomide

Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the European Hematology Association (EHA). This results showed that lenalidomide, an immunomodulator, provided clinically significant improved activity irrespective of baseline demographics or disease characteristics when compared with investigator’s choice in patients with relapsed or refractory mantle cell lymphoma.

More from Marek Trněný

Evolving treatment landscape of MCL
John Kuruvilla et al. • 17 Oct 2023
2:28
Improving outcomes for R/R DLBCL with polatuzumab vedotin
Marek Trněný • 14 Jun 2018
1:59
Rituximab maintenance key to outcome improvement in mantle cell lymphoma
Marek Trněný • 14 Jun 2018
3:12
Prognostic indices for follicular lymphoma: PRIMA-PI
Marek Trněný • 14 Jun 2018

Related Videos

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:25
The future of CAR-T for the treatment of lymphoma
Anna Sureda • 7 Mar 2024
2:40
The impact of CAR-T on the role of SCT in lymphoma
Anna Sureda • 7 Mar 2024
0:44
A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
Stefania Bramanti • 17 Feb 2024
The content of VJHemOnc is intended for healthcare professionals